Trichloroacetic Acid in Different Concentrations: A Promising Treatment Modality for Vitiligo.


Journal

Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
ISSN: 1524-4725
Titre abrégé: Dermatol Surg
Pays: United States
ID NLM: 9504371

Informations de publication

Date de publication:
01 02 2021
Historique:
pubmed: 23 8 2020
medline: 27 4 2021
entrez: 23 8 2020
Statut: ppublish

Résumé

Despite the recent advances in the treatment of vitiligo, results are still largely unsatisfactory and many patients show either weak or no response to treatment. Few clinical trials have investigated the use of trichloroacetic acid (TCA) to induce repigmentation in stable vitiligo. To evaluate the efficacy and safety of TCA, in different concentrations, for the treatment of stable localized vitiligo. The study included 100 patients with acral/nonacral stable vitiligo. Trichloroacetic acid was applied, as a monotherapy, to the vitiliginous patches at different concentrations according to the treated site every 2 weeks until complete repigmentation or for a maximum of 6 treatment sessions. Follow-up was done every month for 6 months to detect any recurrence. Eyelid vitiligo showed the highest response to TCA treatment (excellent response in 80% of cases), followed by the face, trunk, and extremities. Lower response rates were noticed in the hands and feet vitiligo. Adverse effects were transient and insignificant in few patients. Trichloroacetic acid seems to be a potential, cost-effective, well-tolerated therapeutic option for the treatment of vitiligo in the adults and pediatric populations.

Sections du résumé

BACKGROUND
Despite the recent advances in the treatment of vitiligo, results are still largely unsatisfactory and many patients show either weak or no response to treatment. Few clinical trials have investigated the use of trichloroacetic acid (TCA) to induce repigmentation in stable vitiligo.
OBJECTIVE
To evaluate the efficacy and safety of TCA, in different concentrations, for the treatment of stable localized vitiligo.
METHODS
The study included 100 patients with acral/nonacral stable vitiligo. Trichloroacetic acid was applied, as a monotherapy, to the vitiliginous patches at different concentrations according to the treated site every 2 weeks until complete repigmentation or for a maximum of 6 treatment sessions. Follow-up was done every month for 6 months to detect any recurrence.
RESULTS
Eyelid vitiligo showed the highest response to TCA treatment (excellent response in 80% of cases), followed by the face, trunk, and extremities. Lower response rates were noticed in the hands and feet vitiligo. Adverse effects were transient and insignificant in few patients.
CONCLUSION
Trichloroacetic acid seems to be a potential, cost-effective, well-tolerated therapeutic option for the treatment of vitiligo in the adults and pediatric populations.

Identifiants

pubmed: 32826599
pii: 00042728-202102000-00020
doi: 10.1097/DSS.0000000000002736
doi:

Substances chimiques

Trichloroacetic Acid 5V2JDO056X

Types de publication

Clinical Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e53-e57

Informations de copyright

Copyright © 2020 by the American Society for Dermatologic Surgery, Inc. Published by Wolters Kluwer Health, Inc. All rights reserved.

Références

Barros JA, Machado Filho CDS, Martins LC, Pettinati J, et al. Vitiligo: avaliação histológica e clínica após curetagem seqüencial. An Bras Dermatol 2007;82:327–35.
Mihăilă B, Dinică RM, Tatu AL, Buzia OD. New insights in vitiligo treatments using bioactive compounds from Piper nigrum. Exp Ther Med 2019;17:1039–44.
Sarveswari KN. Cosmetic camouflage in vitiligo. Indian J Dermatol 2010;55:211–4.
Puri N, Puri A. A comparative study on 100% TCA versus 88% phenol for the treatment of vitiligo. Our Dermatol 2012;3:184–6.
Hunter N, Mashaly H, Dorgham D, And Ismail S. Trichloroacetic acid peel 15% + NB-UVB versus trichloroacetic acid peel 25% + NB-UVB for stable non-segmental vitiligo. Med J Cairo Univ 2016;84:959–63.
El Mofty M, Esmat S, Hunter N, Mashaly HM, et al. Effect of different types of therapeutic trauma on vitiligo lesions. Dermatol Ther 2017;30:e12447.
Bhor U, Pande S. Scoring systems in dermatology. Indian J Dermatol Venereol Leprol 2006;72:315–21.
Khunger N; IADVL Task Force. Standard guidelines of care for chemical peels. Indian J Dermatol Venereol Leprol 2008;74(Suppl):S5–12.
Ortonne JP, Bissett DL. Latest insights into skin hyperpigmentation. J Investig Dermatol Symp Proc 2008;13(1):10–4.
Kimura A, Kanazawa N, Li HJ, Yonei N, et al. Influence of trichloroacetic acid peeling on the skin stress response system. J Dermatol 2011;38:740–7.
Brody HJ: Complications of chemical peeling. In: Brody HJ. editor. Chemical Peeling. St. Louis, MO: Mosby Year Book Inc.; 1992; pp. 121–45.
Halder RM, Nordlund JJ. Topical treatment of pigmentary disorders. In: Nordlund JJ, Boissy RE, Hearing VJ, King RA, et al, editors. The Pigmentary System (2nd ed). Malden, MA: Blackwell Publishing; 2006; pp. 1165–74.
Falabella R. Vitiligo and the melanocyte reservoir. Indian J Dermatol 2009;54:313–8.
Travis LB, Weinberg JM, Silverberg NB. Successful treatment of vitiligo with 0.1% tacrolimus ointment. Arch Dermatol 2003;139:571–3.
Esmat SM, El-Tawdy AM, Hafez GA, Zeid OA, et al. Acral lesions of vitiligo: why are they resistant to photochemotherapy? J Eur Acad Dermatol Venereol 2012;26:1097–104.
De Padova MP, Tosti A. Complications of superficial and medium chemical peel. In: Tosti A, Beer KR, De Padova MP, editors. Management of Complications of Cosmetic Procedures.Berlin, Germany: Springer Verlag; 2012; pp. 2.

Auteurs

Ahmad Nofal (A)

Dermatology, Venereology and Andrology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.

Mohamed M Fawzy (MM)

Dermatology, Venereology and Andrology Department, Faculty of Medicine, Tanta University, Tanta, Egypt.

Rania Alakad (R)

Dermatology, Venereology and Andrology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH